Arbutus Biopharma
ABUS
51 hedge funds and large institutions have $47.6M invested in Arbutus Biopharma in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
24,060% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $5K
79% more capital invested
Capital invested by funds: $26.5M → $47.6M (+$21M)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
6% more funds holding
Funds holding: 48 → 51 (+3)
0.25% less ownership
Funds ownership: 38.13% → 37.88% (-0.25%)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$2.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 3 |
Squarepoint
New York
|
+$458K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$335K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$286K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.85M |
| 2 |
Millennium Management
New York
|
-$1.02M |
| 3 |
HP
Hound Partners
New York
|
-$580K |
| 4 |
Goldman Sachs
New York
|
-$448K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$278K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$278K | -169,908 | Closed |
|
|
SIM
52
Spark Investment Management
New York
| – | -$28K | -28,026 | Closed |
|
|
HF
53
HRT Financial
New York
| – | -$11K | -11,700 | Closed |
|
54
State Street
Boston,
Massachusetts
| – | -$12K | -11,686 | Closed |
|
55
Group One Trading
Chicago,
Illinois
| – | -$8.96K | -5,476 | Closed |
|
56
JP Morgan Chase
New York
| – | +$54 | +33 | New |
|
ABUS Hedge Fund Activity: Q2 2020 in Review
51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2020, worth a combined $47.6M — up 79% from $26.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABUS positions and 9 closed out — a net gain of 3 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.14M. The largest seller was Citadel Advisors, cutting an estimated $1.85M.
- 51 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2020, up from 48 in Q1 2020.
- Funds reported $47.6M of Arbutus Biopharma stock for Q2 2020, up 79% quarter-over-quarter.
- 12 funds opened new Arbutus Biopharma positions in Q2 2020 and 9 closed out, a net change of +3 holders.
- The largest Arbutus Biopharma buyer in Q2 2020 was Morgan Stanley, an estimated $2.14M added.
- The largest Arbutus Biopharma seller in Q2 2020 was Citadel Advisors, an estimated $1.85M sold.
Based on aggregated 13F filings for Q2 2020.